Stephen Senn, Prof Statistics, Univ of Glasgow, Willi Maurer, Global Head Statistical Methodology, Novartis
Stephen Senn, Prof Statistics, Univ of Glasgow,
Willi Maurer, Global Head Statistical Methodology, Novartis
If you really feel uncomfortable around statistics, Senn and Maurer made this session more understandable and enjoyable. The audience laughed a lot, this is most likely the secret to Prof Senn's success with students. The presenters discussed how statistics or biostatistics has changed in the world of clinical R&D to a position of becoming an integral player in R&D.
Also discussed was the use of Bayesian statistics especially as new tools in analysis methods to support innovative and dynamic trial design. Both speakers discussed how dynamic a tool Bayesian statistics can be, and how effectively it can be used in the conclusion section when making a decision about a drug. Prof Senn's book, Dicing with Death, is a great way to get more expertise on the subject and laugh at the same time.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.